Business Wire

VertiGIS Enters Next Phase of Growth, Appoints Andy Berry as CEO

15.11.2022 16:00:00 EET | Business Wire | Press release

Share

VertiGIS, a global market leader and provider of innovative spatial asset management solutions for utilities, telecommunications, government, and infrastructure organizations is entering its next phase of growth and expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005035/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

London-based Andy Berry joins VertiGIS as CEO. (Photo: Business Wire)

VertiGIS is backed by global, technology-focused investment firm Battery Ventures, who saw an opportunity to bring together a distributed ecosystem of leading geographic information systems (GIS) and spatial technology companies under the brand in 2017. VertiGIS has since acquired 10 businesses in North America and Europe and shows no signs of slowing down; in fact, the company intends to grow both organically and through acquisition over the coming years to expand VertiGIS’s offerings into their target industries around the world.

Leading the charge for this new phase of rapid growth is London-based Andy Berry, who was recently appointed as VertiGIS’s CEO. Berry has an extensive background in growing global technology companies with executive roles at ZephyrTel, Pitney Bowes, and LogFire. In his most recent role as Executive Vice President (International, Compass Business Unit) at Infor he was responsible for USD $300 million of revenue across seven independent business units with over 100 products that served 20,000 customers in EMEA and Asia.

“It’s impressive to see how VertiGIS has come together and evolved over the past five years,” said Berry. “This next stage of our growth is all about innovation. While our customers can certainly rely upon us to continue supporting them with our trusted, in-market solutions, they can also expect to see us apply our decades of industry experience and research into cutting-edge technology as we continue to invest in configurable, cloud-ready software that solves their real-world challenges.”

Morad Elhafed, a Battery general partner and VertiGIS board member, noted: “We are thrilled to welcome Andy to the team to further VertiGIS’s mission, which has never been more important given recent geopolitical events impacting governments across Europe, a key VertiGIS customer segment. More broadly, we’re excited to support the company’s organic and inorganic growth strategies across all segments and geographies going forward.”

VertiGIS currently employs over 500 employees in nine countries and serves over 5,000 customers – ranging in size from small businesses and municipalities to global enterprises and major cities – around the world. Their proven, configurable solutions address challenges commonly faced by utilities, telecommunications, government, and infrastructure organizations, with use cases such as:

  • Network management (planning, documentation, simulation, analytics);
  • Citizen engagement;
  • Land management and urban planning;
  • Waste management;
  • Facilities and asset management (critical infrastructure, large building operations, commercial spaces, manufacturing plants); and
  • Transportation (roads, rail, airports, seaports).

VertiGIS solutions are powered by the flexible, purposeful capabilities (e.g., web and mobile viewers, reporting and printing designers, fine-grained security tools, intelligent workflows to digitize processes) found in their VertiGIS Studio™ suite, which can also be licensed separately to help customers extend, enhance, or create their own spatial applications quicker with configuration instead of writing costly custom code.

About VertiGIS:

VertiGIS is a leading spatial asset management and geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, government, telecommunications, and infrastructure professionals connect their business processes to location technology. The VertiGIS product portfolio is used by over 5,000 customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Further information at www.vertigis.com.

About Battery Ventures:

Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andy Berry, Chief Executive Officer – VertiGIS
Website: www.vertigis.com
Email: andy.berry@vertigis.com
Phone: +44 (0)7718 118689

Rebecca Buckman, Marketing Partner – Battery Ventures
Website: www.battery.com
Email: becky@battery.com
Phone: +1 650 292 2077

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye